bezafibrate has been researched along with pioglitazone in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (58.33) | 29.6817 |
| 2010's | 9 (37.50) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
| Andersen, AS; Brand, CL; Bury, PS; Fleckner, J; Jeppesen, L; Lehmann, SV; Mogensen, JP; Mortensen, SB; Panajotova, V; Pettersson, I; Polivka, Z; Rasmussen, HB; Sauerberg, P; Sindelar, K; Sturis, J; Svensson, LA; Wassermann, K; Wöldike, HF; Wulff, EM; Ynddal, L | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Kimura, H; Momose, Y; Moriyama, S; Odaka, H; Sakamoto, J; Sawada, H; Sugiyama, Y | 1 |
| Kotake, H | 1 |
| Nakagawa, M; Onishi, T; Saibara, T; Saika, K; Shizuta, Y; Sugiura, T; Takeda, K; Toda, K | 1 |
| Fujita, H; Hirose, H; Kawai, T; Miyashita, K; Ogawa, T; Saruta, T; Seto, Y; Ukeda, K; Yajima, K; Yamada, T; Yamamoto, Y | 1 |
| Itoh, M; Kitamura, T; Niho, N; Noda, T; Shoji, Y; Sugimura, T; Takahashi, M; Wakabayashi, K | 1 |
| Narce, M; Poisson, JP | 1 |
| Brand, CL; Pickavance, LC; Wassermann, K; Wilding, JP | 1 |
| Mutoh, M; Niho, N; Wakabayashi, K | 1 |
| Inoue, R; Kobara, M; Miki, S; Morita, Y; Murakami, M; Nakata, T; Nakayama, Y; Sawai, N; Shimizu, T; Toba, H; Tsukamoto, R; Yoshimura, A | 1 |
| Kawakami, M; Kawano, M; Senba, H | 1 |
| Akagami, T; Doi, T; Masuyama, T; Mori, Y; Naka, T; Ohyanagi, M; Sakoda, T; Tsujino, T | 1 |
| Akita, N; Fukutomi, T; Gonzalez, FJ; Hossain, MA; Kimura, G; Ogata, M; Staels, B; Suzuki, S; Tsujita, M; Yokoyama, S | 1 |
| He, JG; Lu, XH; Lv, GP; Si, SY; Zhang, H; Zhao, BH; Zheng, ZH | 1 |
| Balasubramanian, R; Cobelli, C; Dalla Man, C; English, PT; Firbank, MJ; Gerrard, J; Lane, A; Taylor, R | 1 |
| Beller, M; Giese, AK; Gläser, A; Lukas, J; Pockrandt, AM; Pohlers, S; Rolfs, A; Runge, F; Seemann, S; Sharif, M; Zheng, C | 1 |
| Benavidez, JM; Black, M; Blednov, YA; Edenberg, HJ; Ferguson, LB; Foroud, T; Goate, AM; Harris, RA; Hesselbrock, V; Schoenhard, GL; Wetherill, L | 1 |
| Barger, JL; Cray, NL; Hester, SN; Mastaloudis, A; Newton, MA; Prolla, TA; Pugh, TD; Vann, JM; Weindruch, R; Wood, SM | 1 |
| Abdelrahman, AM; El-Tahawy, NF; Ibrahim, SA; Mohamed, MZ | 1 |
3 review(s) available for bezafibrate and pioglitazone
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
[Syndrome X].
Topics: Animals; Bezafibrate; Biguanides; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hyperinsulinism; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Leptin; Life Style; Metabolic Syndrome; Pioglitazone; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2002 |
Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice.
Topics: Age Factors; Animals; Benzamides; Bezafibrate; Cyclooxygenase 2; Genes, APC; Humans; Hyperlipidemias; Intestinal Polyps; Lipoprotein Lipase; Membrane Proteins; Mice; Organophosphorus Compounds; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Triglycerides | 2006 |
21 other study(ies) available for bezafibrate and pioglitazone
| Article | Year |
|---|---|
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
Topics: Animals; Blood Glucose; Carbazoles; Cholesterol; Cholesterol, Dietary; Crystallography, X-Ray; Drug Evaluation, Preclinical; Glucose Tolerance Test; Hypoglycemic Agents; Hypolipidemic Agents; Male; Mice; Models, Molecular; Nuclear Proteins; Phenylpropionates; Pioglitazone; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2002 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.
Topics: Animals; Apolipoprotein A-I; Bezafibrate; Chlorocebus aethiops; Chromans; COS Cells; Fenofibrate; Gene Expression Regulation; Humans; Hypoglycemic Agents; Kinetics; Pioglitazone; Protein Isoforms; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Transfection; Troglitazone; Tumor Cells, Cultured | 2000 |
Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency.
Topics: Aging; Animals; Aromatase; Bezafibrate; Blood Glucose; Cholesterol; Estradiol; Glucose Tolerance Test; Insulin; Insulin Resistance; Male; Mice; Mice, Knockout; Models, Animal; Obesity; Pioglitazone; Testosterone; Thiazoles; Thiazolidinediones; Triglycerides | 2003 |
Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice.
Topics: Animals; Bezafibrate; Body Weight; Diabetes Mellitus; Drug Therapy, Combination; Glucose; Glucose Transporter Type 2; Insulin; Insulin Secretion; Islets of Langerhans; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Monosaccharide Transport Proteins; Pancreas; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Thiazolidines; Transcription Factors | 2003 |
Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands.
Topics: Age Factors; Animals; Bezafibrate; Cholesterol; Fatty Acids, Nonesterified; Genes, APC; Hyperlipidemias; Intestinal Polyposis; Intestine, Small; Ligands; Lipoprotein Lipase; Liver; Mice; Mice, Inbred C57BL; Mice, Knockout; Pioglitazone; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazolidinediones; Transcription Factors; Triglycerides | 2003 |
Novel PPARgamma-dependent and independent effects for thiazolidinediones.
Topics: Animals; Bezafibrate; Body Weight; Chromans; Diabetes Mellitus, Type 2; Gene Expression; Humans; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Proteins; Mice; Monocytes; Pancreas; Pioglitazone; PPAR alpha; PPAR gamma; Pregnancy Proteins; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Troglitazone; Tumor Necrosis Factor-alpha | 2003 |
The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats.
Topics: Adipose Tissue; Animals; Bezafibrate; Body Composition; Body Weight; Diabetes Mellitus; Diet; Energy Metabolism; Glucose Clamp Technique; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Obesity; Organ Size; Oxazines; Pancreas; Phenylpropionates; Pioglitazone; PPAR alpha; PPAR gamma; Rats; Rats, Inbred Strains; Receptors, Cell Surface; Receptors, Leptin; Thiazolidinediones | 2005 |
The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aorta, Thoracic; Bezafibrate; Blood Glucose; Blotting, Western; Diabetes Mellitus, Experimental; Gene Expression; Hypoglycemic Agents; Hypolipidemic Agents; Injections, Intraperitoneal; Insulin; Lipid Metabolism; Male; NADPH Oxidase 4; NADPH Oxidases; Osteopontin; Peptidyl-Dipeptidase A; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazolidinediones; Vascular Cell Adhesion Molecule-1 | 2006 |
Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone.
Topics: Bezafibrate; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; Pioglitazone; Thiazolidinediones | 2006 |
Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes.
Topics: Aldosterone; Angiotensin II; Animals; Animals, Newborn; Bezafibrate; Cells, Cultured; DNA Primers; Dose-Response Relationship, Drug; Endothelin-1; Interleukin-18; Myocytes, Cardiac; NF-kappa B; Oligopeptides; Peptides, Cyclic; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Piperidines; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; Thiazolidinediones | 2008 |
On the mechanism for PPAR agonists to enhance ABCA1 gene expression.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Bezafibrate; Cell Line, Tumor; Fenofibrate; Fibroblasts; Gemfibrozil; Gene Expression Regulation; Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pioglitazone; PPAR delta; PPAR gamma; Propionates; Thiazoles; Thiazolidinediones; Triazoles | 2009 |
Impacts of different promoters on the mammalian one-hybrid assay for detecting nuclear receptor agonists.
Topics: Animals; Bezafibrate; Cells, Cultured; Chenodeoxycholic Acid; Drug Discovery; Genetic Vectors; HeLa Cells; High-Throughput Screening Assays; Humans; Hydrocarbons, Fluorinated; Ligands; Mice; NIH 3T3 Cells; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Promoter Regions, Genetic; Pyrimidines; Rosiglitazone; Sensitivity and Specificity; Structure-Activity Relationship; Sulfonamides; Thiazolidinediones; Two-Hybrid System Techniques | 2010 |
Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
Topics: Abdominal Muscles; Adult; Aged; Bezafibrate; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Liver; Middle Aged; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Triglycerides | 2010 |
Enzyme enhancers for the treatment of Fabry and Pompe disease.
Topics: 1-Deoxynojirimycin; Acetylcysteine; alpha-Galactosidase; alpha-Glucosidases; Ambroxol; Bezafibrate; Enzyme Activators; Fabry Disease; Gene Expression; Glycogen Storage Disease Type II; HEK293 Cells; Humans; Leupeptins; Lysosomes; Pioglitazone; Plasmids; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Stability; Recombinant Proteins; Thiazolidinediones; Transfection | 2015 |
Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humans.
Topics: Adult; Alcohol Drinking; Alcoholism; Alkanesulfonates; Animals; Bezafibrate; Brain; Female; Fenofibrate; Genome-Wide Association Study; Humans; Liver; Male; Mice; Phenylpropionates; Pioglitazone; Polymorphism, Single Nucleotide; PPAR alpha; PPAR gamma; Thiazoles; Thiazolidinediones | 2015 |
Identification of tissue-specific transcriptional markers of caloric restriction in the mouse and their use to evaluate caloric restriction mimetics.
Topics: 2,4-Dinitrophenol; Adipose Tissue, White; Aging; Animals; Bezafibrate; Caloric Restriction; Carnitine; Citrate (si)-Synthase; Gene Expression Profiling; Gene Expression Regulation; Glycated Hemoglobin; Interferon-gamma; Male; Metformin; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Inbred DBA; Mice, Inbred Strains; Muscle, Skeletal; Myocardium; Neocortex; Pioglitazone; Quercetin; Resveratrol; Sirtuin 3; Stilbenes; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2017 |
Antifibrotic effects of bezafibrate and pioglitazone against thioacetamide-induced liver fibrosis in albino rats.
Topics: Actins; Animals; Bezafibrate; Hepatic Stellate Cells; Liver; Liver Cirrhosis; Liver Function Tests; Male; Malondialdehyde; Nitrites; Pioglitazone; Rats; Thioacetamide | 2021 |